Multiple myeloma is a complex hematological malignancy characterized by the abnormal proliferation of plasma cells in the bone marrow. While it primarily affects the bones and blood, its influence on ocular health is often overlooked. In this article, we explore the relationship between multiple myeloma and ocular manifestations, shedding light on potential symptoms, risks, and management strategies for patients and healthcare professionals alike.

Multiple myeloma is a type of cancer that arises from plasma cells, a type of white blood cell responsible for producing antibodies. In multiple myeloma, malignant plasma cells accumulate in the bone marrow, interfering with normal blood cell production and causing skeletal destruction. Common symptoms include bone pain, weakness, anemia, and increased susceptibility to infections. While multiple myeloma primarily affects the skeletal system and blood, its systemic nature can impact various organs and tissues, including the eyes.

Patients with multiple myeloma may experience several ocular manifestations, which can vary in severity and presentation. Some of the common eye conditions associated with multiple myeloma include:

• Retinopathy: Multiple myeloma-associated retinopathy can manifest as retinal hemorrhages, cotton-wool spots, and vascular abnormalities, leading to visual disturbances and potential vision loss.
• Optic Neuropathy: Compression of the optic nerve by adjacent bone lesions or infiltration of malignant cells can result in optic neuropathy, characterized by visual field defects, decreased visual acuity, and color vision abnormalities.
• Conjunctival and Orbital Involvement: Rarely, multiple myeloma can involve the conjunctiva or orbit, presenting as masses, swelling, or proptosis (bulging of the eyes), which may require biopsy for diagnosis and management.
• Dry Eye Syndrome: Systemic manifestations of multiple myeloma, such as dehydration and medication side effects, can contribute to dry eye syndrome, leading to ocular discomfort and irritation.

Managing ocular manifestations of multiple myeloma involves a collaborative approach between oncologists, hematologists, and ophthalmologists. Treatment strategies may include:

• Systemic therapy targeting the underlying multiple myeloma, such as chemotherapy, immunomodulatory drugs, or targeted therapies.
• Localized treatments for ocular complications, including intraocular injections, laser therapy, or surgical intervention for severe cases.
• Supportive measures to alleviate symptoms and improve ocular comfort, such as artificial tears, lubricating ointments, and protective eyewear.

Regular ophthalmic evaluation and monitoring are crucial for patients with multiple myeloma to detect and manage ocular complications early, optimizing visual outcomes and quality of life.

In conclusion, multiple myeloma can impact ocular health through various mechanisms, ranging from retinopathy and optic neuropathy to conjunctival and orbital involvement. Awareness of these ocular manifestations is essential for early detection, prompt intervention, and comprehensive management of patients with multiple myeloma. By fostering collaboration between healthcare providers and prioritizing ocular health in the context of multiple myeloma care, we can improve patient outcomes and enhance overall well-being.

World Eye Care Foundation’s eyecare.live brings you the latest information from various industry sources and experts in eye health and vision care. Please consult with your eye care provider for more general information and specific eye conditions. We do not provide any medical advice, suggestions or recommendations in any health conditions.